Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259938 | 0.84 | MAPT (0.52) | MAPTHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL6260058 | 0.80 | MAPT (0.52) | MAPTHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL3196009 | 0.80 | GPR6 (0.40) | RAB9AKMT2ANPC1NR1H4MEN1 | |
| SCHEMBL6255305 | 0.78 | MAPT (0.52) | MAPTHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL3187488 | 0.76 | ALDH1A1 (0.44) | MAPTHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL3207077 | 0.75 | PDE10A (0.47) | MAPTALDH1A1LMNAALOX15MAPK1 | |
| SCHEMBL6262123 | 0.75 | SRD5A2 (0.47) | MAPTHDAC1ALDH1A1HSD17B10RAB9A | |
| SCHEMBL5224056 | 0.73 | F10 (0.61) | MAPTHDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL395599 | 0.73 | MAPT (0.74) | MAPTALDH1A1LMNAALOX15APEX1 | |
| SCHEMBL19830567 | 0.73 | MAPT (0.74) | MAPTALDH1A1LMNAALOX15APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0999834-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6586459-B2 | Inhibitors of factor Xa; for example 3-(4-tert-butylbenzoyl)amino-N-(4-methoxyphenyl)-2-thiophenecarboxamide | BEIGHT DOUGLAS WADE (US) | 2003-07-01 | — | — | US | disclosed |
| US-6583173-B2 | Useful as anticoagulants in mammals; inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-06-24 | — | — | US | disclosed |
| US-20020072531-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-06-13 | — | — | US | disclosed |
| US-20020049234-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-04-25 | — | — | US | disclosed |
| US-6313151-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072531-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | MAPT 4730/4885HDAC1 592/4885HDAC3 624/4885 |
| US-20020049234-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | MAPT 4730/4885HDAC1 592/4885HDAC3 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.